Gα₁₃/PDZ-RhoGEF/RhoA Signaling Is Essential for Gastrin-Releasing Peptide Receptor–Mediated Colon Cancer Cell Migration

Maulik Patel, Takeharu Kawano, Nobuchika Suzuki, Takao Hamakubo, Andrei V. Karginov, and Tohru Kozasa

Department of Pharmacology, University of Illinois at Chicago College of Medicine, Chicago, Illinois (M.P., A.V.K., T.Ko.); Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, Virginia (T. Ka.); and Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan (N.S., T.H., T.Ko.).

Received May 19, 2014; accepted June 13, 2014

ABSTRACT

Gastrin-releasing peptide receptor (GRPR) is ectopically expressed in over 60% of colon cancers. GRPR expression has been correlated with increased colon cancer cell migration. However, the signaling pathway by which GRPR activation leads to increased cancer cell migration is not well understood. We set out to molecularly dissect the GRPR signaling pathways that control colon cancer cell migration through regulation of small GTPase RhoA. Our results show that GRP stimulation activates RhoA predominantly through G13 heterotrimeric G-protein signaling. We also demonstrate that postsynaptic density 95/disk-large/ZO-1 (PDZ)-RhoGEF (PRG), a member of regulator of G-protein signaling (RGS)-homology domain (RH) containing guanine nucleotide exchange factors (RH-RhoGEFs), is the predominant activator of RhoA downstream of GRPR. We found that PRG is required for GRP-stimulated colon cancer cell migration, through activation of RhoA–Rho-associated kinase (ROCK) signaling axis. In addition, PRG-RhoA-ROCK pathway also contributes to cyclo-oxygenase isoform 2 (Cox-2) expression. Increased Cox-2 expression is correlated with increased production of prostaglandin-E₂ (PGE₂), and Cox-2–PGE₂ signaling contributes to total GRP-mediated cancer cell migration. Our analysis reveals that PRG is overexpressed in colon cancer cell lines. Overall, our results have uncovered a key mechanism for GRPR-regulated colon cancer cell migration through the Gα₁₃-PRG-RhoA-ROCK pathway.

Introduction

Gastrin-releasing peptide (GRP) receptor (GRPR) has been found to be ectopically expressed or overexpressed in small-cell lung cancer (SCLC), breast cancer, prostate cancer, and colon cancer (Jensen et al., 2008). In colon cancer, several studies support the role of GRPR in increasing tumor cell proliferation (Radulovic et al., 1991; Frucht et al., 1992), and morphogenetic transformation leading to increased tumor cell differentiation (Carroll et al., 1999). GRPR has also been shown to stimulate colon cancer cell motility (Glover et al., 2005). However, the molecular mechanisms by which GRPR activation leads to colon cancer cell migration are not well understood.

GRPR is a seven-transmembrane G-protein coupled receptor (GPCR) that couples to members of the G₁₁ and G₁₂/₁₃ families of heterotrimeric G-proteins (Jensen et al., 2008). GRPR-mediated cancer cell proliferation is thought to be primarily regulated through activation of G₁₃ canonical signaling pathway (Cutitta et al., 1985; Rozengurt, 1998; Jensen et al., 2008). In comparison with G₁₃ signaling, relatively little is known about G₁₃-mediated pathways downstream of GRPR and their contributions to colon cancer progression. Receptors coupled to G₁₃ are known to activate small GTPase RhoA that controls cell migration (Wang et al., 2004; Mikelis et al., 2013). This is accomplished by direct interaction of activated G₁₃ with the family of guanine nucleotide exchange factors (GEFs) for RhoA known as regulator of G-protein signaling (RGS)-homology domain (RH) containing guanine nucleotide exchange factors (RH-RhoGEFs). The RH-RhoGEF subfamily consists of p115RhoGEF (p115), postsynaptic density 95/disk-large/ZO-1 (PDZ)-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG) (Hart et al., 1996, 1998; Kozasa et al., 1998; Fukuhara et al., 1999, 2000; Tanabe et al., 2004). GTP-bound G₁₃ interacts with the RH domain of these large multidomain-containing GEFs. This interaction stimulates their GEF activity leading to activation of RhoA (Hart et al., 1996, 1998; Kozasa et al., 1998; Chen et al., 2008). GRP-stimulated RhoA activation is known to be regulated by RH-RhoGEFs, is the predominant activator of RhoA downstream of GRPR. We found that PRG is required for GRP-stimulated colon cancer cell migration, through activation of RhoA–Rho-associated kinase (ROCK) signaling axis. In addition, PRG-RhoA-ROCK pathway also contributes to cyclo-oxygenase isoform 2 (Cox-2) expression. Increased Cox-2 expression is correlated with increased production of prostaglandin-E₂ (PGE₂), and Cox-2–PGE₂ signaling contributes to total GRP-mediated cancer cell migration. Our analysis reveals that PRG is overexpressed in colon cancer cell lines. Overall, our results have uncovered a key mechanism for GRPR-regulated colon cancer cell migration through the Gα₁₃-PRG-RhoA-ROCK pathway.

A.K. and T. Kozasa contributed equally to this work as co-corresponding senior authors.

dx.doi.org/10.1124/mol.114.093914.

ABBREVIATIONS: Cox-2, cyclo-oxygenase isoform 2; FBS, fetal bovine serum; GEFIG, guanine nucleotide exchange factor; GFP, green fluorescent protein; GRP, gastrin-releasing peptide; GRPR, GRP receptor; GST, glutathione S-transferase; HEK, human embryonic kidney; LARG, leukemia-associated RhoGEF; p115, p115RhoGEF; PDZ, postsynaptic density 95/disk-large/ZO-1; PRG, PDZ-RhoGEF; PGE₂, prostaglandin E₂; RGS, regulator of G-protein signaling; RH, regulator of G-protein signaling homology domain; ROCK, Rho-associated kinase; siRNA, small-interfering RNA; Y-27632, (1R,4r)-4-((F)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide.
activation downstream of GRPR in colon cancer cells has not been established.

Activation of RhoA is known to contribute to tumorigenesis by playing a role in cellular transformation, proliferation, migration, and invasion (Sahai and Marshall, 2002). Several studies have shown that RhoA is overexpressed and highly activated in many solid tumors, including colon cancer (Fritz et al., 1999; Karlsson et al., 2009). Increased RhoA activation and signaling through its downstream effectors, such as Rho-associated kinase (ROCK), contributes to cancer progression. Activation of the RhoA-ROCK signaling axis initiates cytoskeletal changes that are essential for cancer cell motility and invasion, initiates gene transcription, and promotes cancer cell proliferation (Yagi et al., 2011; Vigil et al., 2012; Zhang et al., 2013). It is currently unknown if GRPR-mediated RhoA-ROCK signaling plays a role in regulation of colon cancer cell migration.

In this report, we have elucidated the signaling pathway downstream of GRPR that is critical for colon cancer cell migration. We have determined that PRG is the dominant GEF mediating RhoA activation downstream of GRPR in colon cancer cells. We have demonstrated that GRPR signaling through G13-PRG-RhoA axis is critical for colon cancer cell migration. Furthermore, we also report that GRP-stimulated PRG-RhoA-ROCK signaling regulates cyclo-oxygenase-2 (COX-2) expression, and that COX-2 activity contributes to the overall GRP-stimulated colon cancer cell migration.

**Materials and Methods**

Human gastrin-releasing peptide was purchased from Sigma-Aldrich (St. Louis, MO), celecoxib and Y-27632 ([1R,4r]-4-((R)-1-aminophenyl)-N-(pyridin-4-yl)cyclohexanecarboxamide) were purchased from Tocris (Bristol, UK), Primary Human Colonic Epithelial Cells (CacoEpic) lysate was purchased from ScienCell Research Laboratories (Carlsbad, CA). Normal human distal colon mucosal sample (male sample) was a gift from Pradeep Dudeja, University of Illinois at Chicago.

**Cell Culture and Transfection.** Caco-2 and HT-29 cells (gift from Richard Benya, Loyola Medicine Chicago, IL) were maintained in base medium consisting of Dulbecco’s modified Eagle’s medium (DMEM) with high glucose, glutamine, and sodium pyruvate, along with Ham’s F12 medium with glutamine. Caco-2 cells were cultured in base medium supplemented with 20% fetal bovine serum (FBS), and HT-29 supplemented with 10% FBS. Human embryonic kidney (HEK293T) cells were cultured in DMEM supplemented with 10% FBS. All cell culture reagents were purchased from Invitrogen/Life Technologies (Grand Island, NY). Caco-2 cells were transfected with Silencer Select PRG small-interfering (siRNA (s19005) with the sequence 5′-GAGAAGAAACCGCUCCAAAT-3′, Silencer Select PRG siRNA (s19006) with sequence 5′-CCGAAAACCUUCCUCAAT-3′, and Silencer Select Negative control no. 1 siRNA (AM4611) purchased from Invitrogen. G13 knockdown was achieved by siGENOME Human G13 siRNA (s19007) with sequence 5′-GAGAAGAAACCGCUCCAAAT-3′, Silencer Select Negative control no. 1 siRNA (AM4611) purchased from Invitrogen. G13 knockdown was achieved by siGENOME Human G13 siRNA—SMARTpool (M-009948-00-0005) consisting of four G13—specific siRNA sequences 5′-GAGAAGAAACCGCUCCAAAT-3′, 5′-CCGAAAACCUUCCUCAAT-3′, 5′-GAGAAGAAACCGCUCCAAAT-3′ purchased from GE Healthcare/Pharmaco (La Fayette, CO). Small-interfering (siRNA) transfection was done with Lipofectamine RNAiMax per manufacturer's protocol from Invitrogen. All experiments utilizing cells with siRNA knockdown were conducted 48 hours after siRNA transfection, and postserum starvation for 16 hours. All cells were between 50 to 70% confluent when experiments were carried out.

**Western Blotting.** Cells were lysed in 20 mM HEPES (pH 7.6), 1% Triton-X-100, 150 mM NaCl, 5 mM MgCl2, 2 mM Na2VO4, 1 mM β-glycerophosphate, aprotinin (16 μg/ml), and leupeptin (3.2 μg/ml). Cell lysates were then clarified by centrifugation at 14,500 RPM for 10 minutes at 4°C. Protein concentration of the lysate was then verified with Bio-Rad DC purchased from Bio-Rad (Hercules, CA). SDS-PAGE sample buffer was then added to the lysate and the samples were boiled for 3 minutes and resolved by SDS-PAGE. Protein was then transferred to nitrocellulose membrane (GE Healthcare) and blocked with 5% milk in Tris-buffered saline and Tween 20 (T-BST) for 1 hour at room temperature. Membranes were then incubated with one of the following antibodies at 4°C: anti-RhoA monoclonal, anti-PDZ-RhoGEF polyclonal, anti-LARG polyclonal (gift from Takao Hamakubo University of Tokyo, 1:1000), anti-p115 polyclonal, anti-GAPDH monoclonal, anti–Green Fluorescent Protein (GFP) polyclonal, anti-Cox-2 polyclonal from Cell Signaling Technology (Danvers, MA), anti-Ga13 polyclonal, anti-Ga13 polyclonal B680 (1:1000) (Singer et al., 1994), anti-Gαq1 polyclonal, anti-Gα12 polyclonal, and anti-beta-actin monoclonal from Sigma-Aldrich. All other antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX). Membranes were then probed with horseradish peroxidase–conjugated secondary antibodies from Amersham (GE Healthcare Life Sciences, Piscataway, NJ). Western blots were developed with SuperSignal West Pico Chemiluminescent Substrate from Thermo Scientific (Rockford, IL). Densitometry was performed with ImageJ software.

**RhoA GTPase Pull-Down Assay.** Rho activity in cultured cells was assessed utilizing the manufacturer’s (Cytoskeleton, Inc., Denver, CO) protocol. Briefly, colon cancer cells were serum-starved for 16 hours. After stimulation, the cells were lysed at 4°C in buffer containing 50 mM Tris-HCl pH 7.5, 900 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 2 mM Na2VO4, aprotinin (16 μg/ml), and leupeptin (3.2 μg/ml). The lysates were then incubated with glutathione S-transferase (GST)-Rho-GTP binding domain of Rhotekin bound to glutathione-Sepharose beads purchased from Cytoskeleton, Inc. (Denver, CO). The samples were washed three times with wash buffer (per manufacturer’s instructions), and then resuspended in SDS-PAGE sample buffer. Samples were then analyzed by Western blot with monoclonal RhoA antibody.

**Purification of GST-RhoA(G13) Recombinant Protein.** Plasmid construct for the prokaryotic expression of GST-RhoA(G13) was provided by K. Burridge (University of North Carolina). Purification of GST-RhoA(G13) was carried out as previously described (Garcia-Mata et al., 2006). Briefly, expression of GST-RhoA(G13) in BL21- CodonPlus (DE3)-RP purchased from Stratagene/Agilent Technologies (Santa Clara, CA) was induced with 200 μM isopropyl-β-D-thiogalactoside (IPTG) for 16 hours at 18°C. Bacterial cells were then lysed with 20 mM HEPES (pH 7.6), 1% Triton-X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol (DTT), aprotinin (16 μg/ml), and leupeptin (3.2 μg/ml). Protein was purified by incubating glutathione-Sepharose 4B beads, purchased from GE Healthcare, at 4°C for 45 minutes. Sepharose beads were then washed with lysis buffer twice and twice with 20 mM HEPES (pH 7.6), 150 mM NaCl, 5 mM MgCl2, and 1 mM dithiothreitol. Protein concentration was estimated with Coomassie Plus protein reagent (Thermo Scientific). The beads were then aliquoted and snap frozen with liquid nitrogen and stored at –80°C.

**GST-RhoA(G13) Pull-Down Assay.** Activation of RH-RhoGEFs was monitored with GST-RhoA(G13) pull-down assay as previously described (Garcia-Mata et al., 2006). Briefly, Caco-2 cells were stimulated with 100 nM GRP for indicated time(s), after which cells were then lysed with 20 mM HEPES (pH 7.6), 1% Triton-X-100, 150 mM NaCl, 5 mM MgCl2, 2 mM Na2VO4, aprotinin (16 μg/ml), and leupeptin (3.2 μg/ml) at 4°C. Protein concentration of lysates was verified with Bio-Rad DC (Biorad), and equal protein and volume of lysate was incubated with 30 μg of purified GST-RhoA(G13)-bound glutathione-Sepharose beads for 45 minutes at 4°C. Samples were then washed three times with lysis buffer without 1% Triton-X-100, and the beads were resuspended in SDS-PAGE sample buffer. Samples were then analyzed by Western blot with RH-RhoGEF–specific antibodies.

**Generation of Lentivirus.** The cDNAs encoding GFP, GFP-RH-GRK2 (1-178aa of bovine GRK2), and GFP-RH-RGS3 (378-519aa of human RGS3) were subcloned under EF-1α promoter of lentivirus.
Intracellular Calcium Measurement. Agonist-induced intracellular calcium mobilization was performed in serum-free condition with GFP, RH-RGS3, and RH-GRK2 expressing Caco-2 cells with GFP-Certified FluoForte calcium assay kit for microplates according to manufacturer’s protocol (Enzo Life Sciences, Farmingdale, NY). Intracellular calcium mobilization was monitored by Molecular Devices (Sunnyvale, CA) FlexStation System. Fluorescence was monitored at Ex = 530 nm/Em = 570 nm. Data obtained as ratio of fold increase after stimulation over basal.

Prostaglandin E$_2$ Enzyme-Linked Immunosorbent Assay. Cell culture media was collected at 4°C after incubating with GRP (100 nM) for indicated time(s). Cell culture media was then centrifuged at 8000 RPM to clear cellular debris. Culture media was then either assayed or stored at –80°C for no longer than 7 days. Concentration of prostaglandin E$_2$ (PGE$_2$) in the culture media was obtained using PGE$_2$ Express ELISA Kit following manufacturer’s protocol (Cayman Chemical, Ann Arbor, MI).

Cell Migration Assays. Cells were serum-starved for 16 hours prior to the assay. Caco-2 and HT-29 cells were plated on the upper chamber of six-well 8.0-μm-pore polycarbonate membrane insert (Corning, Tewksbury, MA) at a density of 5 × 10$^5$ cells/well. The inserts were placed in 1% FBS containing media with or without GRP (100 nM) added to the lower chamber. The plate was then placed in the incubator at 37°C supplemented with 5% CO$_2$. Cells were allowed to migrate for 8 hours, after which the cells on the top of the chamber were mechanically removed and the inserts were washed with PBS. The cells were fixed with 4% paraformaldehyde for 10 minutes (Electron Microscopy Sciences, Hatfield, PA) and stained with 2% crystal violet (Sigma-Aldrich) for 5 minutes. Migrated cells on the lower chamber were visualized with a microscope and counted.

Data Analysis and Statistics. Statistical and graphical analysis was conducted with GraphPad Prism 5 (La Jolla, CA). Data are represented as mean ± S.E.M of at least n = 3 independent experiments. Statistical analysis was performed with one-way analysis of variance followed by Bonferroni’s multiple comparison test.

Results

GRP Stimulation Increases RhoA Activation in Colon Cancer Cells. GRP expression is absent in normal colonic epithelial cells (Carroll et al., 1999). However, its ectopic expression on colon cancer cells contributes to tumorigenesis by stimulating cell proliferation and migration (Frucht et al., 1992; Jensen et al., 2008). Previous studies indicate that GRPR can promote tumorigenicity through activation of the small

---

**Fig. 1.** GRP stimulation results in RhoA activation in colon cancer cell lines. Time-course of RhoA activation in colon cancer cell lines in response to GRP stimulation. Caco-2 (A) and HT-29 cells (B) serum-starved and then incubated with GRP for indicated time(s). Cell lysates were used for GST-RBD pulldown (see Materials and Methods). The precipitate and lysate samples were then used for Western blot to detect RhoA and GAPDH. GAPDH is used as loading control. (D) Statistical densitometric analysis of n = 4. Shown are mean values ± S.E.M.; ***P < 0.001. RBD, Rho binding domain.

**Fig. 2.** Ga$_{13}$ predominantly mediates RhoA activation downstream of GRPR in Caco-2 cells. (A, B) Caco-2 cells transfected with scrambled or Ga$_{13}$-SMARTpool siRNA for 48 hours to obtain Ga$_{13}$-specific knockdown without affecting Ga$_{12}$ expression. (+) Ga$_{12}$/Ga$_{13}$ lanes contain purified recombinant Ga$_{12}$ or Ga$_{13}$ subunits used as positive control. (C) Caco-2 cells were serum-starved overnight and then stimulated with GRP for 10 minutes and subsequently used for GST-RBD pulldown (see Materials and Methods). Precipitate and lysate samples were then immunoblotted to detect RhoA, Ga$_{13}$, and GAPDH. GAPDH was used as loading control. (D) Statistical densitometric analysis of n = 4. Shown are mean values ± S.E.M.; ***P < 0.001. RBD, Rho binding domain.
GTPase RhoA in prostate cancer (Zheng et al., 2006). However, the role of RhoA signaling downstream of GRPR in colon cancer has not been well studied. Thus, we first sought to determine whether activation of GRPR leads to activation of RhoA in colon cancer cells. As a model we used Caco-2 and HT-29 colon cancer cell lines, which express functional GRP receptor and form moderately well-differentiated adenocarcinoma in nude mice (Carroll et al., 2000). To determine RhoA activation, we conducted a time-course experiment, stimulating Caco-2 and HT-29 cells in serum free conditions with a concentration of GRP (100 nM) that has been used for previous colon cancer studies (Ferris et al., 1997; Glover et al., 2005). The level of RhoA activation was assessed using RhoA pulldown assay (Ren and Schwartz, 2000) (Fig. 1A and B). Stimulating colon cancer cells with GRP increased the fraction of RhoA in the active GTP-bound state. The activation of RhoA reaches maximum at about 10 minutes and decreases over time out to 60 minutes after GRP addition in both Caco-2 and HT-29 cells. These data indicate that GRPR activation on colon cancer cells initiates signaling pathway(s) that leads to RhoA activation.

\textbf{Go13 Is the Principal Mediator of RhoA Activation Downstream of GRPR.} GRPR signaling is in part conducted through activation of the alpha subunits of Go and G12/13 heterotrimeric G-proteins in colon cancers (Jensen et al., 2008). However, the contribution of each G-protein to GRPR-mediated activation of RhoA in colon cancer cells has not been established. To address this question, we used siRNA to downregulate endogenous Go13 expression in Caco-2 cells. Go13 siRNA efficiently and specifically decreased Go13 expression in Caco-2 cells (Fig. 2A) without affecting expression of its close structural homolog Go12 (Fig. 2B). Downregulation of Go13 expression led to a significant decrease in GRP-stimulated RhoA activation, indicating that in Caco-2 cells RhoA activation predominantly occurs through Go13 (Fig. 2, C and D).

Go13 can also activate RhoA through direct interaction with RhoGEFs such as p63RhoGEF, Tric, and Kalirin (Aittaleb et al., 2010). To determine the role of Go13 in mediating RhoA activation in Caco-2 cells, we transduced Caco-2 cells with lentivirus expressing GFP fused to the RH domain of RGS3 or G-protein coupled receptor kinase 2 (GRK2). Both of these proteins specifically bind to activated Go13 and inhibit Go13-mediated signaling (Carman et al., 1999; Scheschonka et al., 2000). As shown in Fig. 3A, both RH-RGS3 and RH-GRK2 coimmunoprecipitated with AlF4-activated endogenous Go13. Caco-2 cells expressing RH-RGS3 and RH-GRK2 also had a defect in GRP-stimulated rise in intracellular Ca2+, a known indicator of GRPR-mediated Go13 signaling, in comparison with GFP-expressing cells (Fig. 3, B and C). These cells were then stimulated with GRP, and lysates were used for RhoA pulldown. Expression of RH-RGS3 or RH-GRK2 led to a small reduction in the amount of activated RhoA (Fig. 3D). The data indicate that Go13 activation is essential for the efficient activation of RhoA downstream of GRPR in colon cancer cells.

\textbf{Fig. 3.} Go13 makes a small contribution to total RhoA activation downstream of GRPR. (A) HEK293T cells were infected with lentivirus for GFP, GFP-conjugated RH-RGS3, or RH-GRK2. After 48 hours, cells were harvested and lysed in the buffer containing either GDP or GDP-AlF4-. Lysates were subjected to Western blotting to confirm protein expression of Go13 (lower panel, lanes 7–12) and GFP, RH-RGS3, or RH-GRK2 (upper panel, lanes 7–12). Immunoprecipitation was carried out using anti-Go13 antibody (lanes 1–6). RH-GRK2 (lane 4, upper) and RH-RGS3 (lane 6, upper) were coimmunoprecipitated with endogenous Go13 activated by GDP-AlF4-. (B,C) Caco-2 cells stably expressing GFP, RH-RGS3, and RH-GRK2 were used to monitor GRP-induced calcium mobilization (see Materials and Methods). Shown are representative traces of at least three independent experiments, from which area under the curve (AUC) was quantitated and plotted (**P < 0.01). (D) Caco-2 cells stably expressing GFP, RH-RGS3, and RH-GRK2 were serum-starved overnight and then stimulated with GRP for 10 minutes. Cell lysates were then used for GST-RBD pulldown (see Materials and Methods). Precipitate and lyse samples were then immunoblotted to detect RhoA, GFP, and p115. Expression of GFP, RH-RGS3, RH-GRK2 in the lysate was confirmed with anti-GFP antibody. p115 was used as loading control. (E) Statistical densitometric analysis of n = 5. Shown are mean values ± S.E.M.; *P < 0.05, ***P < 0.001. RBD, Rho binding domain.
reduction in RhoA activation in response to GRP stimulation (Fig. 3, D and E). This indicates that Gαq makes a minor contribution to total RhoA activation downstream of GRPR, and that Gα13 is the predominant mediator of RhoA signaling.

**PRG Is the Primary RH-RhoGEF Activated Downstream of GRPR.** GPCRs coupled to G12/13 family of heterotrimeric G-proteins can initiate RhoA signaling by physically interacting with and activating RH-RhoGEFs. Previous studies have suggested that GPCRs coupled to G12/13 use distinct RH-RhoGEFs to activate RhoA signaling (Wang et al., 2004). In Caco-2 cells all three RH-RhoGEF family members (p115, PRG, and LARG) are expressed. (Fig. 4, A–C). Thus, to identify which RH-RhoGEF(s) are activated in response to GRP stimulation, we used GST-RhoAG17A fusion protein as an affinity reagent to isolate activated GEFs for RhoA. The glycine-to-alanine mutation in the recombinant RhoA protein mimics the nucleotide-free state of RhoA which binds with high affinity to activated GEFs (Garcia-Mata et al., 2006). Employing this biochemical approach, we isolated activated GEFs from Caco-2 cells treated with GRP in a time course experiment. Our data reveal that GRP stimulation resulted in strong activation of PRG as indicated by increased PRG pulldown throughout our time-course (Fig. 4A). The maximum activity was detected at 10 minutes after addition of GRP, consistent with the peak of RhoA activity that we observed. In contrast, GRP treatment of Caco-2 cells did not affect activation of LARG and p115 (Fig. 4, B–D). Thus, our data demonstrates that GRPR stimulation predominantly activates PRG in colon cancer cells.

**PRG Is The Primary Activator of RhoA Downstream of GRPR.** Our RhoAG17A pulldown data reveal that GRP stimulation predominantly activates PRG. This suggests that PRG should be the predominant activator of RhoA downstream of GRPR in colon cancer cells. To confirm this hypothesis, we downregulated expression of PRG using two different siRNA reagents (Fig. 5A). Importantly, treatment with these siRNAs did not affect expression of the two related RH-RhoGEFs, LARG and p115 (Fig. 5A). We then performed a RhoA pulldown with siRNA-transfected cells to determine the role of PRG in RhoA activation in response to GRP stimulation. As shown in Figs. 5, B–E, PRG knockdown significantly decreased GRP-stimulated RhoA activation in Caco-2 and HT-29 cells. Similar decrease in RhoA activation was also observed with the PRG siRNA-2 reagent. Importantly, the decrease in RhoA activation was similar to the effect achieved by downregulation of Gα13 (Fig. 2A). Thus, these data suggest that GRP-mediated RhoA activation in colon cancer cells occurs primarily through the Gα13-PRG signaling axis.

**The PRG-RhoA-ROCK Axis Mediates GRP-Stimulated Colon Cancer Cell Migration.** Cancer cell motility is an essential process of cancer progression and invasion. RhoA is known to play a critical role in regulation of focal adhesions and stress fiber formation leading to cell migration (Ridley and Hall, 1992; Hopkins et al., 2007; Yagi et al., 2011). RhoA has been shown to be overexpressed in colon cancers (Fritz et al., 1999). Here we have shown that PRG is the predominant activator of RhoA downstream of GRPR in colon cancer cells. This evidence suggests that PRG should regulate colon cancer cell migration downstream of GRPR. To test this hypothesis we conducted a Transwell cell migration assay using Caco-2 and HT-29 cells transfected with scrambled siRNA or PRG siRNA. As shown in Fig. 6, A and B, PRG knockdown resulted in a dramatic reduction in GRP-stimulated colon cancer cell migration almost to a level equivalent to unstimulated scrambled siRNA-treated cells. This demonstrates that PRG is a critical mediator of colon cancer cell migration downstream of GRPR.

**ROCK is one of the key downstream effectors of RhoA and is known to contribute to RhoA-mediated regulation of cancer cell migration and invasion (Vishnubhotla et al., 2007; Yagi et al., 2011). Therefore, to determine the role of ROCK in**
GRP-stimulated colon cancer cell migration, we conducted the Transwell assay with Caco-2 cells treated with or without ROCK inhibitor Y-27632 (20 μM) in the presence or absence of GRP. As shown in Fig. 6C, ROCK inhibition arrested GRP-stimulated Caco-2 cell migration. In agreement with previous reports, unstimulated Caco-2 cells treated with Y-27632 did have a slight increase in basal cell migration in comparison with cells with no treatment (Hopkins et al., 2007; Makrodouli et al., 2011). Nonetheless, our results indicate that ROCK is required for efficient GRP-stimulated colon cancer cell migration. Overall, our data demonstrate that in colon cancer cells, GRP-stimulated migration is regulated via the PRG-RhoA-ROCK pathway.

**PRG Contributes to Cox-2 Expression and PGE2 Production.** Cox-2 plays a critical role in colon cancer development and progression. Studies have shown that 85% of colon cancers have increased Cox-2 expression (Wang and Dubois, 2010). GRPR signaling has been implicated in regulation of Cox-2 expression in variety of tissues via different mechanisms (Slice et al., 1999; Corral et al., 2007). However, the role of Gα13-mediated signaling pathway in regulation of Cox-2 expression in colon cancer cells has not been elucidated. Hence, we set out to determine if Gα13 signaling downstream of GRPR, specifically the PRG-RhoA-ROCK axis, plays a role in Cox-2 expression. As shown in Fig. 7, A and B, Cox-2 expression is increased upon GRP stimulation in both Caco-2 and HT-29 cells. Cox-2 expression is increased in these cancer cells at 4 and 8 hours after GRP addition. Next, we looked at the role of PRG in regulation of Cox-2 expression in Caco-2 and HT-29 cells downstream of GRPR. Downregulation of PRG expression using siRNA reduced Cox-2 expression after 8 hours of treatment with GRP (Fig. 7, C–F). It is well known that Cox-2 expression drives colon cancer progression through the production of PGE2 (Mutoh et al., 2002; Wang and Dubois, 2010). In fact, PGE2 is the predominant prostaglandin found in colon cancer (Rigas et al., 1993). So we next examined if the decrease in Cox-2 expression in PRG siRNA-transfected cells is associated with a decrease in PGE2 production. We used enzyme-linked immunosorbent assay to quantify PGE2 concentration in the media of scrambled or PRG siRNA-transfected cells stimulated with GRP. As shown in Figs. 7, G and H, PRG knockdown inhibited GRP-induced production of PGE2 in comparison with scrambled siRNA-treated cells stimulated with GRP. These data show that GRPR-Gα13 signaling through PRG regulates Cox-2 expression and PGE2 production.

**Rho-ROCK-Mediated Regulation of Cox-2-PGE2 Production Contributes to Overall GRP-Stimulated Cancer Cell Migration.** Having identified that PRG-RhoA signaling plays a role in GRP-stimulated Cox-2 expression, we questioned if this regulation is mediated through ROCK. ROCK has previously been implicated in regulation of Cox-2 expression in different tissues (Benitah et al., 2003; Hirota et al., 2012). Here we used Y-27632 (20 μM) to inhibit ROCK and assess its effect on Cox-2 expression in response to GRP. ROCK inhibition abrogates GRP-mediated stimulation of Cox-2 expression in...
Cox-2 expression and PGE2 production in colon cancer cells. Here we conducted a Transwell cell migration assay with Caco-2 cells stimulated with GRP incubated with or without celecoxib, a Cox-2-specific inhibitor. It has been reported that celecoxib at 20 μM does not result in colon cancer cell apoptosis (Xiao et al., 2008). Caco-2 cells incubated with celecoxib without GRP had no defect in basal cell migration in comparison with dimethyl sulfoxide–treated Caco-2 cells (Fig. 8F). However, celecoxib treatment did result in a modest reduction (≈35%) in GRP-stimulated migration of Caco-2 cells as compared with Caco-2 cells treated with both GRP and dimethyl sulfoxide (Fig. 8F). Thus, our data indicates that Cox-2 expression and activity contributes to overall GRP-mediated colon cancer cell migration.

PRG Expression Is Upregulated in Colon Cancer Cells. Our data show that PRG is critical in regulation of cell migration stimulated though GRPR. Enhanced propagation of GRPR signaling in colon cancer cells might be achieved by elevated expression of PRG. Evaluation of PRG protein levels demonstrated higher PRG expression in Caco-2 and HT-29 colon cancer cells compared with primary Human Colonic Epithelial Cells (HCepiC) and samples from normal human distal colonic mucosa (DCM) (Fig. 9A). Furthermore, analysis of copy number variation for RH-RhoGEFs in Catalogue of Somatic Mutations in Cancer database (COSMIC) revealed that 17.1% of the 486 tested human colon cancers have gains in PRG gene copy number (COSMIC v68) (Fig. 9B). These results indicate that PRG expression may be elevated in colon cancers, playing a critical role in regulation of colon cancer cell migration and invasion.

Discussion

GPCRs coupled to GRα_{12/13} have been implicated in cancer progression via increased cancer cell migration and invasion in small-cell lung cancer, breast cancer, prostate cancer, and colon cancer (Lappano and Maggiolini, 2011). In our current work, we have identified the molecular mechanism by which GRPR-activated GRα_{12/13} signaling contributes to colon cancer cell migration. We have found that GRα_{12} is the predominant mediator of RhoA activation downstream of GRPR, whereas GRα_{q} makes small contributions to total RhoA activation. This observation, along with previous studies demonstrating that chemokine (C-X-C) motif receptor 4 (CXCR4) and lysophosphatidic acid (LPA) receptors mediate RhoA activation through GRα_{12} (Bian et al., 2006; Yagi et al., 2011), suggests that GRα_{12} possibly is the predominant regulator of RhoA activity downstream of multiple GPCRs that couple to GRα_{12/13}.

Our studies identify PRG as the predominant RH-RhoGEF activated downstream of GRPR in colon cancer cells, whereas the other two RH-RhoGEFs, p115 and LARG, have little or no change in activity as indicated by our RhoA pulldown data. Interestingly, downregulation of PRG expression leads to a similar decrease in RhoA activation as inhibition of GRα_{13}, indicating that GRα_{13} regulates RhoA through PRG. The remaining GRα_{q}-mediated contribution to activation of RhoA may possibly be regulated through Trio, Kalirin, LARG, or p63RhoGEF. A previous report has demonstrated that LARG may be a downstream effector of GRα_{q} (Booden et al., 2002); however, our RhoA pulldown data does not support this possibility, as GRP-stimulation brings about no further increase in LARG activation in colon cancer cells. It has been shown that

- Cox-2 expression and PGE2 production in colon cancer cells.
- PRG expression is upregulated in colon cancer cells.
- PRG plays a critical role in regulation of colon cancer cell migration and invasion.
p63RhoGEF, a RhoA-specific GEF, is activated through the direct interaction of AlF₄-activated Go₄ subunit with the C-terminal extension of p63RhoGEF’s PH domain (Lutz et al., 2005; Rojas et al., 2007). Indeed, we have observed that p63RhoGEF is activated upon GRP stimulation in Caco-2 cells and thus presumably contributes to Go₄-mediated RhoA activation (Patel and Kozasa, unpublished data). However, this novel pathway requires further characterization.

GPCR-mediated RhoA-ROCK activation plays a critical role in cell migration. Here, we report for the first time that GRP-stimulated colon cancer cell migration is regulated by the PRGRhoA-ROCK signaling axis. Our findings are in line with previous studies, which have reported that PRG-RhoA-ROCK signaling regulates fibroblast cell migration and breast cancer cell migration. These studies have identified that PRG-RhoA-ROCK signaling regulates cell migration through induction of adhesion complexes and spatial regulation of actomyosin contractile machinery (Iwanicki et al., 2008; Struckhoff et al., 2013). Prior work has also demonstrated that growth factor receptor tyrosine kinases also use Rho-ROCK signaling to promote tumor cell migration and invasion (Somlyo et al., 2000; Harrison et al., 2013). Hence, it is clear that ROCK can be an ideal molecular target for prevention of tumor cell migration and metastasis.

GPCR-mediated regulation of Cox-2 expression contributes to colon cancer progression by regulating proliferation, migration, and invasion (Wang and Dubois, 2010). Here we show that GRP stimulation of Caco-2 and HT-29 cells leads to Cox-2 expression. Our data for the first time supports the role of PRG in regulation of Cox-2 expression and Cox-2-mediated PGE₂ production. Furthermore, we identified that ROCK, acting downstream of PRG-RhoA, contributes to Cox-2 expression in response to GRP stimulation. Our findings are in line with other studies that have also reported the role of ROCK in regulating Cox-2 expression downstream of another GPCR, proteinase-activated receptor-2 (Hirota et al., 2012). Current evidence indicates that Cox-2-PGE₂ signaling stimulates colon cancer cell migration through activation of its cognate prostaglandin...
E receptor 4 or through transactivation of epidermal growth factor receptor (Buchanan et al., 2003; Hawcroft et al., 2012). Overall our data suggests that the modest defect in cancer cell motility observed with celecoxib treatment indicates that Cox-2-PGE2 signaling is not the main regulator of GRP-stimulated colon cancer cell migration, and most probably it is predominantly controlled by PRG-RhoA-ROCK pathway directly regulating actinomyosin contractile machinery.

**Fig. 8.** Rho-ROCK mediated regulation of Cox-2-PGE2 production contributes to overall GRP stimulated cancer cell migration. (A,B) Cox-2 expression in Caco-2 (A) and HT-29 (B) cells treated with or without Y-27632 (20 μM) along with GRP for 8 hours. Cox-2 expression was verified by Western Blot. (C,D) Statistical densitometric analysis of Cox-2 expression in Caco-2 (C) and HT-29 (D) cells from n = 3. Shown are mean values ± S.E.M.; **P < 0.01, ***P < 0.001. (E) Caco-2 cells serum-starved overnight and stimulated with GRP with or without Y-27632 for 8 hours. Cell media for each condition was harvested and analyzed for PGE2 concentration by enzyme-linked immunosorbent assay (ELISA) (see Materials and Methods). Statistical analysis of n = 3. Shown are mean values ± S.E.M.; **P < 0.01. (F) Caco-2 cells serum-starved overnight and plated on the upper chamber of Transwell insert at 5 × 10⁵ cells/well. Transwell inserts were contained in media supplemented with 1% FBS and with or without GRP along with celecoxib (20 μM) (see Materials and Methods). Statistical analysis of cell migration, n = 3 repeated in duplicates. Shown are mean values ± S.E.M.; **P < 0.01, ***P < 0.001. (G) Model of GRPR signaling in colon cancer cells. GRP stimulation increases RhoA activity primarily through Go13-PRG activation. PRG-RhoA-ROCK signaling axis is required for GRP-stimulated colon cancer cell migration (denoted by bolder arrows). PRG-RhoA-ROCK also regulates Cox-2 expression, which makes a small contribution (denoted by dotted arrow) to overall GRP-stimulated colon cancer cell migration (see text for details).

Cox-2-PGE2 signaling is not the main regulator of GRP-stimulated colon cancer cell migration, and most probably it is predominantly controlled by PRG-RhoA-ROCK pathway directly regulating actinomyosin contractile machinery.
The role of RH-RhoGEFs in tumorigenesis has just recently gained recognition. Existing evidence suggests that the role of these RH-RhoGEFs is varied in tumor development and metastasis and their functions are tumor-specific. It has been reported that p115 expression is upregulated in prostate cancer cells and invasive prostate tumors (Huang et al., 2011). However, the role of p115 in the context of its involvement in signaling downstream of GPCRs and its effect on cancer progression is not known. In contrast to elevated expression of p115 in prostate cancer, LARG expression in breast and colon cancers is reported to be decreased. In these cancers, LARG has been reported to act as a tumor suppressor (Ong et al., 2009). Loss of LARG expression in breast and colon cancer is also supported by data that shows that there is loss of gene copy number of LARG in these solid tumors. Here, we show that LARG is the major mediator of GRP-stimulated colon cancer cell migration. Data form the COSMIC database shows that PRG gene copy number is increased in a significant number of colon cancer samples. Furthermore, our results demonstrate that PRG is overexpressed in colon cancer cell lines. These results suggest that PRG may play a key role in regulation of tumorigenesis mediated by GRPR and other GPCRs. Indeed, a recent report by Struckhoff et al. (2013) concludes that PRG is essential for CXCR4-mediated breast cancer cell migration and invasion and found that PRG expression is increased at the leading edge of primary tumors and tumor cells that have undergone lymphatic invasion. Another study looking at PC-3 prostate cancer cells grown in three-dimensional organotypic culture reported increased PRG expression in the invasive cultures (Harma et al., 2012). Furthermore, PRG has been implicated as a prosurvival gene in human glioblastoma, where knockdown of PRG resulted in decreased cell viability (Thaker et al., 2009; Masica and Karchin, 2011). Thus, it is tempting to hypothesize that PRG expression and activity might be increased not only in colon cancer but also in other solid tumors, regulating prosurvival pathways, cancer cell migration, and invasion.

Characterization of GRPR-mediated signaling pathway in colon cancer cells has revealed new potential therapeutic targets. Identification of the role of PRG in GRPR-mediated colon cancer cell migration and Cox-2 expression opens additional opportunities for developing novel therapeutic agents. Application of a recently developed inhibitor specific for RH-RhoGEFs (Y16) together with existing inhibitors for Cox-2 may prove to have therapeutic effects on colon cancer models (Shang et al., 2013). As the roles of the RH-RhoGEFs in tumorigenesis and metastasis become more well-defined, development of novel inhibitors specific for p115, LARG, or PRG would expand our choices for selection of therapeutic strategy.

Fig. 9. PRG expression is upregulated in colon cancer cells. (A) Protein expression of PRG in Caco-2, HT-29, primary human colonic epithelial cells, and two different samples of human distal colon mucosa. (B) Copy number variation (CNV) of three RH-RhoGEF family members in four common types of solid tumors obtained from COSMIC v68. Depicting number variation (CNV) of three RH-RhoGEF family members in four cells, and two different samples of human distal colon mucosa. (B) Copy expression of PRG in Caco-2, HT-29, primary human colonic epithelial

References


Acknowledgments

Authorship Contributions

Patel, Suzuk, Hamakubo.

Conducted experiments: Patel, Kawano.

Contributed new reagents or analytic tools: Suzuki, Hamakubo.

Performed data analysis: Patel, Kawano, Karginov.

Wrote or contributed to the writing of the manuscript: Patel, Kozasa, Karginov.


In the above article [Patel M, Kawano T, Suzuki N, Hamakubo T, Karginov AV, and Kozasa T (2014) Mol Pharmacol 86:252–262], the below funding information was omitted:

This work was supported by National Institute of Health grants [GM61454] to T.K., T32 [HL007829] to M.P., and [R21CA159179] to A.V.K.; and grants from the Ministry of Education, Science, and Technology of Japan, and FIRST program from Japan Society for the Promotion and Science. FIRST represents Funding Program for World-Leading Innovative R&D on Science and Technology. A.V.K. and T.K. contributed equally to this work as co-corresponding senior authors.

The authors regret this error and any inconvenience it may have caused.